Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 33, Issue 6, 2013, Pages 414-421

  Brito, Maricruz Gutiérrez ^a   Thompson, Allison ^b   Girgenti, Douglas ^b   Giardina, Peter C ^b   Sarkozy, Denise A ^c   Gruber, William C ^b   Emini, Emilio A ^c   Scott, Daniel A ^b  

^a Hospital para el Nino Poblano   (Mexico)

^b Pfizervaccine Research   (United States)

^c PFIZER INC   (United States)

Author keywords

Mexico; Pneumococcal vaccines; Pneumonia; Safety

Indexed keywords

CHILD HEALTH; DISEASE PREVALENCE; HEALTH SERVICES; IMMUNITY; IMMUNIZATION; VACCINE;

MEXICO [NORTH AMERICA];

PNEUMOCOCCUS VACCINE; PREVENAR13;

ARTICLE; FEMALE; HUMAN; IMMUNOLOGY; INFANT; MALE; MEXICO; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL;

FEMALE; HUMANS; INFANT; MALE; MEXICO; PNEUMOCOCCAL VACCINES;

EID: 84882327025     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Franco-Paredes C, Lammoglia L, Hernández I, Santos-Preciado JI. Epidemiology and outcomes of bacterial meningitis in Mexican children: 10-year experience (1993-2003). Int J Infect Dis. 2008;12(4):380-6.
2. Castañeda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, Brandão AP, et al. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J. 2009;28(9):e265-70.
3. Espinosa-de Los Monteros LE, Jiménez-Rojas V, Aguilar-Ituarte F, Cashat-Cruz M, Reyes-López A, Rodríguez-Suárez R, et al. Streptococcus pneumoniae isolates in healthy children attending day-care centers in 12 states in Mexico. Salud Publica Mex. 2007;49(4):249-55.
4. Quiñones-Falconi F, Calva JJ, López-Vidal Y, Galicia-Velazco M, Jiménez-Martinez ME, Larios-Mondragón L. Antimicrobial susceptibility patterns of Streptococcus pneumoniae in Mexico. Diagn Microbiol Infect Dis. 2004;49(1):53-8. (Pubitemid 38595627)
5. Agudelo CI, Castañeda E, Corso A, Regueira M, Brandileone MC, Brandão AP, et al. Resistencia a antibióticos no betalactámicos de aislamientos invasores de Streptococcus pneumoniae en niños latinoamericanos. SIREVA II, 2000-2005. Rev Panam Salud Publica. 2009;25(4):305-13.
6. Villaseñor-Sierra A, Lomas-Bautista M, Aguilar-Benavides S, Martínez-Aguilar G. Serotypes and susceptibility of Streptococcus pneumoniae strains isolated from children in Mexico. Salud Publica Mex. 2008;50(4):330-3.
7. Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J. Residual economic burden of Streptococcus pneumoniae-and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine. 2010;28(Suppl 6):G14-22.
8. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8(2):266-72. (Pubitemid 32217054)
9. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10(4):514-9. (Pubitemid 36890430)
10. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125(5):866-75.
11. Gadzinowski J, Daniels E, Scott DA, Patterson S, Gruber WC, Tansey S, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine with/without polysorbate 80 in healthy infants in Poland. Pediatr Infect Dis J. 2009;28(6):e171-2.
12. World Health Organization: WHO Technical Report Series, No. 927, 2005. WHO Expert Committee on Biological Standardization. 54th report. Annex 2: Recommendations for the production and control of pneumococcal conjugate vaccines. Geneva: WHO; 2005. Pp. 66-92.
13. Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17(6):1017-26.
14. Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192-203.
15. Snape MD, Klinger CL, Daniels ED, John TM, Layton H, Rollinson L, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29(12):e80-90.
16. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493-505.
17. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
18. Gómez-Barreto D, de los Monteros LE, López-Enríquez C, Suarez RR, de la Torre C. Streptococcus pneumoniae serotypes isolated from the middle ear of Mexican children diagnosed with acute otitis media. Salud Publica Mex. 2011;53(3):207-11.
19. Chacon-Cruz E, Velazco-Mendez Y, Navarro-Alvarez S, Rivas-Landeros RM, Volker ML, Lopez-Espinoza G. Pneumococcal disease: emergence of serotypes 19A and 7F following conjugate pneumococcal vaccination in a Mexican hospital. J Infect Dev Ctries. 2012;6(6):516-20.
20. Arredondo-Garcia JL, Calderón E, Echániz-Aviles G, Soto-Noguerón A, Arzate P, Amabile-Cuevas CF, et al. Serotypes and antibiotic susceptibility of Streptococcus pneumoniae isolates causative of invasive diseases in Mexican children. J Infect Dev Ctries. 2011;5(2):119-22.
21. Espinosa-de los Monteros LE, Aguilar-Ituarte F, Jiménez- Juárez RN, Rodríguez-Suárez RS, Gómez-Barreto D. Reemplazo de serotipos de Streptococcus pneumoniae en niños con vacuna conjugada antineumocóccica 7V en México. Salud Publica Mex. 2010;52(1):4-13.
22. Reyna J, Limon AE. High prevalence of serotype 11B of Streptococcus pneumoniae isolated in the nasopharynx of Mexican children. Arch Med Res. 2008;39(6):629-30.
23. Mercado EH, Egoavil M, Horna SG, Torres N, Velásquez R, Castillo ME, et al. Serotipos de neumococo en niños portadores antes de la vacunación antineumocócica en el Perú. Rev Peru Med Exp Salud Publica. 2012;29(1): 53-60.
24. Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D. Evaluación económica de un programa de inmunización infantil en México basado en la vacuna neumocócica conjugada 13-valente. Value Health. 2011;14(5 Suppl 1):S65-70.
25. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.
26. Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012;12:101.
27. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-71. (Pubitemid 39453026)
28. Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, et al. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J. 2009;28(11):943-7.
29. Center KJ, Hansen JR, Lewis E, Fireman BH, Hilton B. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009;28(5):438-40.
30. Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72-7.